Reported 4 days ago
BTIG has raised its price target for Insulet (PODD) from $270 to $300, maintaining a Buy rating, as it expects accelerated adoption of the Omnipod among type 2 diabetes patients. The firm is also improving its estimates for U.S. Omnipod sales in FY25 and increasing EBIT margins for 2025 and 2026.
Source: YAHOO